Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS

Phase 2Active Not RecruitingNCT06977451

n-Lorem Foundation1 enrolled

Overview

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Amyotrophic Lateral Sclerosis

Interventions

nL-CHCHD-001DRUG

Personalized Antisense Oligonucleotide

Eligibility

Sex: ALLMin age: 63 YearsMax age: 63 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s). * Ability to travel to the study stie and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records. * Genetically confirmed neurological disorder. Exclusion Criteria: * Participant has any condition that in the opinion of the Site Investigator, would ultimately prevent the completion of study procedures. * Use of an investigational medication within less than 5 half-lives of the drug at enrollment

Locations (1)

Columbia University, Irving Medical Center

New York, New York, United States

Outcomes

Primary Outcomes

Clinical Functioning

Change from baseline at 12-months post nL-CHCHD-001 administration in scores on Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). A maximum score of 48 represents normal functioning, and the minimum score is 0.